Epidemiology
is not responsible for any error and/or omissions arising from translation and adaptation or otherwise. This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.
20 Sun J, Zheng Q, Madhira V, et al . Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US. JAMA Intern Med 2022;182:153–62. 21 Friedman MA, Curtis JR, Winthrop KL. Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis 2021;80:1255–65. 22 Haberman RH, Herati R, Simon D, et al . Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis 2021;80:1339–44. 23 Simon D, Tascilar K, Schmidt K, et al . Humoral and cellular immune responses to SARS-CoV-2 infection and vaccination in autoimmune disease patients with B cell depletion. Arthritis Rheumatol 2022;74:33–7. 24 Furer V, Eviatar T, Zisman D, et al . Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis 2021;80:1330–8. 25 Deepak P, Kim W, Paley MA, et al . Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study. Ann Intern Med 2021;174:1572-1585. 26 Stay up to date with your COVID-19 vaccines, 2022. Available: https://www.cdc. gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html?CDC_AA_refVal=https% 3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fvaccines%2Ffully- vaccinated.html [Accessed 5 Jul 2022]. 27 Melzack R. The short-form McGill pain questionnaire. Pain 1987;30:191–7. 28 Donovan KA, Jacobsen PB, Small BJ, et al . Identifying clinically meaningful fatigue with the fatigue symptom inventory. J Pain Symptom Manage 2008;36:480–7. 29 Hann DM, Jacobsen PB, Azzarello LM, et al . Measurement of fatigue in cancer patients: development and validation of the fatigue symptom inventory. Qual Life Res 1998;7:301–10. 30 Uhlig T, Haavardsholm EA, Kvien TK. Comparison of the health assessment questionnaire (HAQ) and the modified HAQ (MHAQ) in patients with rheumatoid arthritis. Rheumatology 2006;45:454–8. 31 Jenkinson C, Layte R, Jenkinson D, et al . A shorter form health survey: can the SF-12 replicate results from the SF-36 in longitudinal studies? J Public Health Med 1997;19:179–86. 32 McCaw ZR, Tian L, Vassy JL, et al . How to quantify and interpret treatment effects in comparative clinical studies of COVID-19. Ann Intern Med 2020;173:632–7. 33 Royston P, Parmar MKB. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol 2013;13:152. 34 Kim DH, Uno H, Wei L-J. Restricted mean survival time as a measure to interpret clinical trial results. JAMA Cardiol 2017;2:1179–80. 35 Kuodi P, Gorelik Y, Zayyad H. Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021. medRxiv 2022. 36 Bhattacharyya RP, Hanage WP. Challenges in inferring intrinsic severity of the SARS- CoV-2 omicron variant. N Engl J Med 2022;386:e14. 37 Wolter N, Jassat W, Walaza S, et al . Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet 2022;399:437–46. 38 Lewnard JA, Hong VX, Patel MM, et al . Clinical outcomes associated with SARS-CoV-2 omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in southern California. Nat Med 2022;28:1933–43. 39 Severity of disease associated with omicron variant as compared with delta variant in hospitalized patients with suspected or confirmed SARS-CoV-2 infection 2022. 40 Godeau D, Petit A, Richard I, et al . Return-To-Work, disabilities and occupational health in the age of COVID-19. Scand J Work Environ Health 2021;47:408–9. 41 Sudre CH, Murray B, Varsavsky T, et al . Attributes and predictors of long COVID. Nat Med 2021;27:626–31. 42 Righi E, Mirandola M, Mazzaferri F, et al . Determinants of persistence of symptoms and impact on physical and mental wellbeing in long COVID: a prospective cohort study. J Infect 2022;84:566–72. 43 Leon L, Perez-Sancristobal I, Madrid A, et al . Persistent post-discharge symptoms after COVID-19 in rheumatic and musculoskeletal diseases. Rheumatol Adv Pract 2022;6:rkac008. 44 Barbhaiya MJ-K, Levine J, Do H, et al . Risk Factors for “Long Haul” COVID-19 in Rheumatology Outpatients in New York City [abstract]. Arthritis Rheumatol 2021;73. 45 Peluso MJ, Lu S, Tang AF, et al . Markers of immune activation and inflammation in individuals with Postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis 2021;224:1839–48. 46 Visvabharathy L, Hanson B, Orban Z, et al . Neuro-COVID long-haulers exhibit broad dysfunction in T cell memory generation and responses to vaccination. medRxiv 2021. doi:10.1101/2021.08.08.21261763. [Epub ahead of print: 29 Oct 2021].
ORCID iDs Yumeko Kawano http://orcid.org/0000-0003-2423-5982 Yuqing Zhang http://orcid.org/0000-0001-7638-0888 Jeffrey A Sparks http://orcid.org/0000-0002-5556-4618 Zachary S. Wallace http://orcid.org/0000-0003-4708-7038
REFERENCES 1 DiIorio M, Kennedy K, Liew JW, et al . Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 global rheumatology alliance vaccine survey. RMD Open 2022;8:e002587. 2 Di Iorio M, Cook CE, Vanni KMM, et al . DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: a prospective study. Semin Arthritis Rheum 2022;55:152025. 3 Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, et al . BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clin Microbiol Infect 2021;27:1652–7. 4 Di Fusco M, Moran MM, Cane A, et al . Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2. J Med Econ 2021;24:1248–60. 5 Cook C, Patel NJ, D’Silva KM, et al . Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases. Ann Rheum Dis 2022;81:289–91. 6 D’Silva KM, Serling-Boyd N, Wallwork R, et al . Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ’hot spot’. Ann Rheum Dis 2020;79:1156–62. 7 Serling-Boyd N, D’Silva KM, Hsu TY, et al . Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic. Ann Rheum Dis 2021;80:660-666. 8 Organization WH. A clinical case definition of post COVID-19 condition by a Delphi consensus , 2021. 9 Prevention CfDCa. Post-COVID conditions: overview for healthcare providers, 2022. Available: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid- conditions.html [Accessed 23 Sep 2022]. 10 Fernández-de-las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, et al . Defining Post-COVID symptoms (post-acute COVID, long COVID, persistent Post-COVID): an integrative classification. Int J Environ Res Public Health 2021;18:2621. 11 Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol 2021;12:698169. 12 Nalbandian A, Sehgal K, Gupta A, et al . Post-Acute COVID-19 syndrome. Nat Med 2021;27:601–15. 13 Whitaker M, Elliott J, Chadeau-Hyam M, et al . Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun 2022;13:1957. 14 Global Burden of Disease Long COVID Collaborators, Wulf Hanson S, Abbafati C, et al . Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA 2022;328:1604–15. 15 Ballering AV, van Zon SKR, Olde Hartman TC, et al . Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet 2022;400:452–61. 16 Dickerman BA, Gerlovin H, Madenci AL, et al . Comparative effectiveness of BNT162b2 and mRNA-1273 vaccines in U.S. veterans. N Engl J Med 2022;386:105–15. 17 Bajema KL, Dahl RM, Evener SL, et al . Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1700–5. 18 Antonelli M, Penfold RS, Merino J, et al . Risk factors and disease profile of post- vaccination SARS-CoV-2 infection in UK users of the COVID symptom study APP: a prospective, community-based, nested, case-control study. Lancet Infect Dis 2022;22:43–55. 19 Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med 2022;28:1461–7.
Patel NJ, et al . Ann Rheum Dis 2023; 82 :565–573. doi:10.1136/ard-2022-223439
573
Powered by FlippingBook